Results 11 to 20 of about 288,435 (354)
JAAD Case Reports, 2015 In the United States, the incidence of melanoma is increasing faster than any other preventable cancer. Acral melanoma is the fourth most common type of cutaneous melanoma and is frequently diagnosed later in its course compared with melanoma in other anatomic locations. Here we describe a case of highly advanced acral melanoma.
Lambert Smith, Franki +2 more
openaire +2 more sources
Immunotherapy for Advanced Melanoma [PDF]
Journal of Investigative Dermatology, 2008 Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with high dose IL-2. Herein, strategies to boost patient antitumor immunity through vaccination, treatment with agents that augment host immunity, and adoptive cell transfer will be discussed.
Fang, Lei +2 more
openaire +2 more sources
Recent advancements in melanoma management [PDF]
Internal Medicine Journal, 2021 AbstractThe treatment options for patients with melanoma have expanded significantly over the past decade. In particular, the use of targeted therapy and immunotherapy has dramatically transformed the outlook for patients with advanced disease. These treatments are now being utilised as adjuvant therapy for patients with earlier stage melanoma after ...
Tharani Krishnan +2 more
openaire +2 more sources
Dabrafenib plus trametinib versus nivolumab for advanced melanoma
Medwave, 2023 Introduction The incidence of cutaneous melanoma has increased worldwide over the years, and an incidence of 3 cases per 100,000 men and women is estimated in Chile.
Daniela Lahoz +2 more
doaj +1 more source
Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
JACC: Case Reports, 2019 Malignant melanoma demonstrates the highest rate of cardiac metastases. The incidence of melanoma is rising. The prognosis of people with advanced melanoma is generally poor.
Frederik Uttenthal Larsen, MD +2 more
doaj +1 more source
Treatment of Advanced Metastatic Melanoma
Dermatology Practical & Conceptual, 2021 The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the overall survival (OS).
Quaglino, Pietro +5 more
openaire +4 more sources
Frontiers in Oncology, 2018 Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma.
Taku Fujimura +21 more
doaj +1 more source
Frontiers in Oncology, 2023 The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of the
Lucía Vázquez-Montero +4 more
doaj +1 more source
SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma [PDF]
, 2018 Our previous data supported a role for the Stearoyl-CoA desaturase (SCD5) in protection against malignancy, whereby it appears to functionally modify tumor stroma impairing tumor spread.
Bellenghi, Maria +8 more
core +1 more source
Frontiers in Medicine, 2019 Ipilimumab, in combination with nivolumab, is one of the promising drugs that enhance the anti-tumor immune response of patients with advanced melanoma. Since the co-administration of nivolumab with ipilimumab in the neoadjuvant setting expands melanoma ...
Taku Fujimura +7 more
doaj +1 more source